Bozitinib

Drug Profile

Bozitinib

Alternative Names: CBI-3103; CBT-101; PLB-1001

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Crown Bioscience
  • Developer Beijing Pearl Biotechnology; Crown Bioscience
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma; Non-small cell lung cancer
  • Preclinical Solid tumours

Most Recent Events

  • 14 Jun 2017 CBT Pharmaceuticals plans a phase I trial to evaluate the safety, pharmacokinetics and efficacy of CBT 101, in patients with Solid tumours (Late-stage disease) and c-MET dysregulation, in USA (PO, Capsule) (NCT03175224)
  • 04 Apr 2017 CBT Pharmaceuticals announces intention to submit IND application to US FDA for Solid tumours
  • 01 Apr 2017 Preclinical trials in Solid tumours in China before April 2017 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top